Friday, October 28, 2016

Neocard




Neocard may be available in the countries listed below.


Ingredient matches for Neocard



Diltiazem

Diltiazem hydrochloride (a derivative of Diltiazem) is reported as an ingredient of Neocard in the following countries:


  • Bangladesh

International Drug Name Search


Blood Disorders Medications


Drugs associated with Blood Disorders

The following drugs and medications are in some way related to, or used in the treatment of Blood Disorders. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

Topics under Blood Disorders

  • Anemia (257 drugs in 24 topics)

  • Bleeding Disorder (203 drugs in 30 topics)

  • Cryoglobulinemia (1 drug)

  • Exchange Transfusion (0 drugs)

  • Leukemia (128 drugs in 13 topics)

  • Leukocytosis (0 drugs)

  • Lymphoma (104 drugs in 9 topics)

  • Myeloproliferative Disorders (65 drugs in 14 topics)

  • Protein C Deficiency (1 drug)

  • Protein S Deficiency (2 drugs)





Drug List:


Oberdol




Oberdol may be available in the countries listed below.


Ingredient matches for Oberdol



Ibuprofen

Ibuprofen is reported as an ingredient of Oberdol in the following countries:


  • Spain

International Drug Name Search


Babesiosis Medications


Definition of Babesiosis: A rare, often severe infection caused by protozoa of the genus.

Drugs associated with Babesiosis

The following drugs and medications are in some way related to, or used in the treatment of Babesiosis. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.





Drug List:


Idamycin PFS


Idamycin PFS is a brand name of idarubicin, approved by the FDA in the following formulation(s):


IDAMYCIN PFS (idarubicin hydrochloride - injectable; injection)



  • Manufacturer: PHARMACIA AND UPJOHN

    Approval date: February 17, 1997

    Strength(s): 1MG/ML [RLD][AP]

Has a generic version of Idamycin PFS been approved?


Yes. The following products are equivalent to Idamycin PFS:


idarubicin hydrochloride injectable; injection



  • Manufacturer: APP PHARMS

    Approval date: August 4, 2009

    Strength(s): 1MG/ML [AP]


  • Manufacturer: BEDFORD LABS

    Approval date: December 14, 2006

    Strength(s): 1MG/ML [AP]


  • Manufacturer: BEDFORD LABS

    Approval date: May 15, 2007

    Strength(s): 1MG/ML [AP]


  • Manufacturer: SANDOZ

    Approval date: March 29, 2011

    Strength(s): 1MG/ML [AP]

IDARUBICIN HYDROCHLORIDE PFS (idarubicin hydrochloride injectable; injection)



  • Manufacturer: TEVA PARENTERAL

    Approval date: May 1, 2002

    Strength(s): 1MG/ML [AP]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Idamycin PFS. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Idamycin PFS.

See also...

  • Idamycin PFS Consumer Information (Wolters Kluwer)
  • Idamycin PFS Consumer Information (Cerner Multum)
  • Idamycin PFS Advanced Consumer Information (Micromedex)
  • Idamycin PFS AHFS DI Monographs (ASHP)
  • Idarubicin Consumer Information (Wolters Kluwer)
  • Idarubicin Consumer Information (Cerner Multum)
  • Idarubicin Intravenous Advanced Consumer Information (Micromedex)
  • Idarubicin Hydrochloride AHFS DI Monographs (ASHP)

Thursday, October 27, 2016

Zanaflex




In the US, Zanaflex (tizanidine systemic) is a member of the drug class skeletal muscle relaxants and is used to treat Cluster Headaches and Muscle Spasm.

US matches:

  • Zanaflex

  • Zanaflex Capsule

UK matches:

  • Zanaflex 2 and 4mg tablets
  • Zanaflex 2 and 4mg tablets (SPC)

Ingredient matches for Zanaflex



Tizanidine

Tizanidine hydrochloride (a derivative of Tizanidine) is reported as an ingredient of Zanaflex in the following countries:


  • Canada

  • Ireland

  • United Kingdom

  • United States

International Drug Name Search

Glossary

SPC Summary of Product Characteristics (UK)

Click for further information on drug naming conventions and International Nonproprietary Names.

Statinor




Statinor may be available in the countries listed below.


Ingredient matches for Statinor



Atorvastatin

Atorvastatin is reported as an ingredient of Statinor in the following countries:


  • Tunisia

International Drug Name Search


Delewal




Delewal may be available in the countries listed below.


Ingredient matches for Delewal



Flupentixol

Flupentixol is reported as an ingredient of Delewal in the following countries:


  • India

Melitracen

Melitracen is reported as an ingredient of Delewal in the following countries:


  • India

International Drug Name Search


Orphol




Orphol may be available in the countries listed below.


Ingredient matches for Orphol



Dihydroergotoxine

Dihydroergotoxine mesilate (a derivative of Dihydroergotoxine) is reported as an ingredient of Orphol in the following countries:


  • Germany

International Drug Name Search


Niflucan




Niflucan may be available in the countries listed below.


Ingredient matches for Niflucan



Flunarizine

Flunarizine dihydrochloride (a derivative of Flunarizine) is reported as an ingredient of Niflucan in the following countries:


  • Argentina

International Drug Name Search


Vetoprim




Vetoprim may be available in the countries listed below.


In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Vetoprim



Sulfadimidine

Sulfadimidine is reported as an ingredient of Vetoprim in the following countries:


  • Germany

Sulfathiazole

Sulfathiazole is reported as an ingredient of Vetoprim in the following countries:


  • Germany

Trimethoprim

Trimethoprim is reported as an ingredient of Vetoprim in the following countries:


  • Germany

International Drug Name Search


Optisol




Optisol may be available in the countries listed below.


Ingredient matches for Optisol



Sulfacetamide Sodium

Sulfacetamide sodium salt (a derivative of Sulfacetamide) is reported as an ingredient of Optisol in the following countries:


  • Israel

International Drug Name Search


Gilenya


Gilenya is a brand name of fingolimod, approved by the FDA in the following formulation(s):


GILENYA (fingolimod - capsule; oral)



  • Manufacturer: NOVARTIS

    Approval date: September 21, 2010

    Strength(s): 0.5MG [RLD]

Has a generic version of Gilenya been approved?


No. There is currently no therapeutically equivalent version of Gilenya available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Gilenya. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • 2-amino-1,3-propanediol compound and immunosuppressant
    Patent 5,604,229
    Issued: February 18, 1997
    Inventor(s): Fujita; Tetsuro & Sasaki; Shigeo & Yoneta; Masahiko & Mishina; Tadashi & Adachi; Kunitomo & Chiba; Kenji
    Assignee(s): Yoshitomi Pharmaceutical Industries, Ltd.
    Taito Co., Ltd.
    2-Amino-1,3-propanediol compounds of the formula (I) ##STR1## wherein R is an optionally substituted straight- or branched carbon chain, an optionally substituted aryl, an optionally substituted cycloalkyl or the like, and R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are the same or different and each is a hydrogen, an alkyl, an aralkyl, an acyl or an alkoxycarbonyl, pharmaceutically acceptable salts thereof and immunosuppressants comprising these compounds as active ingredients. The 2-amino-1,3-propanediol compounds of the present invention show immunosuppressive action and are useful for suppressing rejection in organ or bone marrow tranplantation, prevention and treatment of autoimmune diseases or as reagents for use in medicinal and pharmaceutical fields.
    Patent expiration dates:

    • February 18, 2014
      ✓ 
      Patent use: TREATMENT OF AUTOIMMUNE DISEASE
      ✓ 
      Drug substance



Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • July 20, 2014 - ADDITION OF THE T1-WEIGHTED GD-ENHANCED LESION EFFICACY VARIABLE IN THE CLINICAL STUDIES SECTION 14 OF THE PACKAGE INSERT

    • September 21, 2015 - NEW CHEMICAL ENTITY

See also...

  • Gilenya Consumer Information (Drugs.com)
  • Gilenya Consumer Information (Wolters Kluwer)
  • Gilenya Consumer Information (Cerner Multum)
  • Gilenya Advanced Consumer Information (Micromedex)
  • Gilenya AHFS DI Monographs (ASHP)
  • Fingolimod Consumer Information (Wolters Kluwer)
  • Fingolimod Consumer Information (Cerner Multum)
  • Fingolimod Advanced Consumer Information (Micromedex)
  • Fingolimod Hydrochloride AHFS DI Monographs (ASHP)

Ofloxacino Genfarma




Ofloxacino Genfarma may be available in the countries listed below.


Ingredient matches for Ofloxacino Genfarma



Ofloxacin

Ofloxacin hydrochloride (a derivative of Ofloxacin) is reported as an ingredient of Ofloxacino Genfarma in the following countries:


  • Spain

International Drug Name Search


Sintenyl




Sintenyl may be available in the countries listed below.


Ingredient matches for Sintenyl



Fentanyl

Fentanyl citrate (a derivative of Fentanyl) is reported as an ingredient of Sintenyl in the following countries:


  • Switzerland

International Drug Name Search


Wednesday, October 26, 2016

Simvax




Simvax may be available in the countries listed below.


Ingredient matches for Simvax



Simvastatin

Simvastatin is reported as an ingredient of Simvax in the following countries:


  • Croatia (Hrvatska)

  • Czech Republic

International Drug Name Search


Nitised




Nitised may be available in the countries listed below.


Ingredient matches for Nitised



Ranitidine

Ranitidine hydrochloride (a derivative of Ranitidine) is reported as an ingredient of Nitised in the following countries:


  • Greece

International Drug Name Search


Servinin




Servinin may be available in the countries listed below.


Ingredient matches for Servinin



Terfenadine

Terfenadine is reported as an ingredient of Servinin in the following countries:


  • Bangladesh

International Drug Name Search


Septéal




Septéal may be available in the countries listed below.


Ingredient matches for Septéal



Chlorhexidine

Chlorhexidine is reported as an ingredient of Septéal in the following countries:


  • Tunisia

Chlorhexidine digluconate (a derivative of Chlorhexidine) is reported as an ingredient of Septéal in the following countries:


  • France

International Drug Name Search


Naurif




Naurif may be available in the countries listed below.


Ingredient matches for Naurif



Granisetron

Granisetron hydrochloride (a derivative of Granisetron) is reported as an ingredient of Naurif in the following countries:


  • Bangladesh

International Drug Name Search


Soya-bean oil




Scheme

Ph. Eur.

CAS registry number (Chemical Abstracts Service)

0008001-22-7

Therapeutic Category

Nutrient

Foreign Names

  • Soiae Oleum raffinatum, ad usum parenterale (Latin)
  • Sojaöl zur parenteralen Anwendung (German)
  • Soja, huile de, pour administration parenterale (French)
  • Aceite de soja (Spanish)

Generic Names

  • Olio di semi di soia (OS)
  • Soybean oil (OS: JAN)
  • Caswell No. 801B (IS)
  • EINECS 232-274-4 (IS)
  • EPA Pesticide Chemical Code 031605 (IS)
  • Huile de Soja pour administration parenterale (IS)
  • Refined undeodorized soybean oil (IS)
  • UNII-241ATL177A (IS)
  • VT 18 (IS)
  • Soiae oleum raffinatum (PH: Ph. Eur. 6)
  • Sojaöl, raffiniertes (PH: Ph. Eur. 6)
  • Soya Oil, Refined (PH: BP 2010)
  • Soya-bean oil, refined (PH: Ph. Eur. 6)
  • Soybean oil (PH: USP 31)

Brand Names

  • Intralipid
    Fresenius, Turkey; Fresenius Kabi, Switzerland; Pharmatel, Australia

International Drug Name Search

Glossary

ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
PHPharmacopoeia Name
Ph. Eur.European Pharmacopoeia

Click for further information on drug naming conventions and International Nonproprietary Names.

Sacietyl




Sacietyl may be available in the countries listed below.


Ingredient matches for Sacietyl



Sibutramine

Sibutramine is reported as an ingredient of Sacietyl in the following countries:


  • Argentina

International Drug Name Search


Dorzo-Vision




Dorzo-Vision may be available in the countries listed below.


Ingredient matches for Dorzo-Vision



Dorzolamide

Dorzolamide hydrochloride (a derivative of Dorzolamide) is reported as an ingredient of Dorzo-Vision in the following countries:


  • Germany

International Drug Name Search


Nu-Amilzide




Nu-Amilzide may be available in the countries listed below.


Ingredient matches for Nu-Amilzide



Amiloride

Amiloride hydrochloride dihydrate (a derivative of Amiloride) is reported as an ingredient of Nu-Amilzide in the following countries:


  • Canada

Hydrochlorothiazide

Hydrochlorothiazide is reported as an ingredient of Nu-Amilzide in the following countries:


  • Canada

International Drug Name Search


Omeprazol Basics




Omeprazol Basics may be available in the countries listed below.


Ingredient matches for Omeprazol Basics



Omeprazole

Omeprazole is reported as an ingredient of Omeprazol Basics in the following countries:


  • Germany

International Drug Name Search


Doxtie




Doxtie may be available in the countries listed below.


Ingredient matches for Doxtie



Doxorubicin

Doxorubicin hydrochloride (a derivative of Doxorubicin) is reported as an ingredient of Doxtie in the following countries:


  • Argentina

  • Ecuador

  • Mexico

International Drug Name Search


Veletri


Veletri is a brand name of epoprostenol, approved by the FDA in the following formulation(s):


VELETRI (epoprostenol sodium - injectable; injection)



  • Manufacturer: ACTELION

    Approval date: June 27, 2008

    Strength(s): EQ 1.5MG BASE/VIAL [RLD]

Has a generic version of Veletri been approved?


No. There is currently no therapeutically equivalent version of Veletri available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Veletri. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Veletri.

See also...

  • Veletri Consumer Information (Wolters Kluwer)
  • Veletri Consumer Information (Cerner Multum)
  • Veletri Advanced Consumer Information (Micromedex)
  • Epoprostenol Consumer Information (Wolters Kluwer)
  • Epoprostenol Consumer Information (Cerner Multum)
  • Epoprostenol Intravenous Advanced Consumer Information (Micromedex)
  • Epoprostenol Sodium AHFS DI Monographs (ASHP)

Tuesday, October 25, 2016

Sandostatin LAR




UK matches:

  • Sandostatin LAR (SPC)

Ingredient matches for Sandostatin LAR



Octreotide

Octreotide is reported as an ingredient of Sandostatin LAR in the following countries:


  • Australia

  • Ecuador

  • Indonesia

  • Taiwan

  • Turkey

Octreotide acetate (a derivative of Octreotide) is reported as an ingredient of Sandostatin LAR in the following countries:


  • Argentina

  • Austria

  • Brazil

  • Chile

  • China

  • Colombia

  • Croatia (Hrvatska)

  • Czech Republic

  • Denmark

  • Germany

  • Hong Kong

  • Hungary

  • Iceland

  • Italy

  • Japan

  • Lithuania

  • Luxembourg

  • Malta

  • New Zealand

  • Norway

  • Oman

  • Peru

  • Poland

  • Portugal

  • Romania

  • Russian Federation

  • Serbia

  • Singapore

  • Slovenia

  • Spain

  • Sweden

  • Switzerland

  • United Kingdom

  • United States

  • Venezuela

International Drug Name Search

Glossary

SPC Summary of Product Characteristics (UK)

Click for further information on drug naming conventions and International Nonproprietary Names.

Viscéralgine




Viscéralgine may be available in the countries listed below.


Ingredient matches for Viscéralgine



Tiemonium Methylsulfate

Tiemonium Methylsulfate is reported as an ingredient of Viscéralgine in the following countries:


  • France

International Drug Name Search


Solac




Solac may be available in the countries listed below.


Ingredient matches for Solac



Lactulose

Lactulose is reported as an ingredient of Solac in the following countries:


  • Indonesia

International Drug Name Search


Varidase




Varidase may be available in the countries listed below.


Ingredient matches for Varidase



Streptokinase-Streptodornase

Streptokinase-Streptodornase is reported as an ingredient of Varidase in the following countries:


  • Austria

  • Finland

  • Germany

  • Norway

  • Taiwan

International Drug Name Search


Humatrope


Humatrope is a brand name of somatropin, approved by the FDA in the following formulation(s):


HUMATROPE (somatropin recombinant - injectable; injection)



  • Manufacturer: LILLY

    Approval date: February 4, 1999

    Strength(s): 12MG/VIAL [RLD], 24MG/VIAL [RLD]

Has a generic version of Humatrope been approved?


No. There is currently no therapeutically equivalent version of Humatrope available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Humatrope. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Humatrope.

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • March 12, 2012 - TREATMENT OF SHORT STATURE IN PEDIATRIC PATIENTS SMALL FOR GESTATIONAL AGE WHO DO NOT MANIFEST CATCH UP GROWTH BY AGE 2 TO 4 YEARS

    • November 1, 2013 - ORPHAN DRUG EXCLUSIVITY

See also...

  • Humatrope Cartridge Consumer Information (Wolters Kluwer)
  • Humatrope Vial Consumer Information (Wolters Kluwer)
  • Humatrope Consumer Information (Cerner Multum)
  • Humatrope Advanced Consumer Information (Micromedex)
  • Somatropin (rDNA origin - Nonrefrigerated) Consumer Information (Wolters Kluwer)
  • Somatropin (rDNA origin - Refrigerated) Consumer Information (Wolters Kluwer)
  • Somatropin (rDNA origin - Refrigerated) Cartridge Consumer Information (Wolters Kluwer)
  • Somatropin (rDNA origin - Refrigerated) Vial Consumer Information (Wolters Kluwer)
  • Somatropin (rDNA origin - Refrigerated) Vials Consumer Information (Wolters Kluwer)
  • Somatropin Consumer Information (Cerner Multum)
  • Somatropin, e-coli derived Subcutaneous, Injection Advanced Consumer Information (Micromedex)
  • Somatropin, mammalian derived Subcutaneous, Injection Advanced Consumer Information (Micromedex)

Lamictal XR


See also: Generic Lamictal, Generic Lamictal CD, Generic Lamictal ODT


Lamictal XR is a brand name of lamotrigine, approved by the FDA in the following formulation(s):


LAMICTAL XR (lamotrigine - tablet, extended release; oral)



  • Manufacturer: SMITHKLINE BEECHAM

    Approval date: May 29, 2009

    Strength(s): 100MG, 200MG, 25MG, 50MG [RLD]


  • Manufacturer: SMITHKLINE BEECHAM

    Approval date: April 14, 2010

    Strength(s): 300MG


  • Manufacturer: SMITHKLINE BEECHAM

    Approval date: June 21, 2011

    Strength(s): 250MG

Has a generic version of Lamictal XR been approved?


No. There is currently no therapeutically equivalent version of Lamictal XR available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Lamictal XR. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Lamictal XR.

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • May 29, 2012 - NEW DOSAGE FORM

    • November 29, 2012 - PEDIATRIC EXCLUSIVITY

    • January 29, 2013 - ADJUNCTIVE THERAPY FOR PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN PATIENTS THIRTEEN YEARS OF AGE AND OLDER

    • April 15, 2014 - MONOTHERAPY IN PATIENTS 13 YEARS OF AGE AND OLDER WITH PARTIAL SEIZURES WHO ARE RECEIVING THERAPY WITH A SINGLE ANTIEPILEPTIC DRUG (AED)

    • April 25, 2014 - MONOTHERAPY IN PATIENTS 13 YEARS OF AGE AND OLDER WITH PARTIAL SEIZURES WHO ARE RECEIVING THERAPY WITH A SINGLE ANTIEPILEPTIC DRUG (AED)

See also...

  • Lamictal XR Extended-Release Tablets Consumer Information (Wolters Kluwer)
  • Lamictal XR Consumer Information (Cerner Multum)
  • Lamictal XR Patient Titration Kit (Blue) Consumer Information (Cerner Multum)
  • Lamictal XR Patient Titration Kit (Green) Consumer Information (Cerner Multum)
  • Lamictal XR Patient Titration Kit (Orange) Consumer Information (Cerner Multum)
  • Lamictal XR Advanced Consumer Information (Micromedex)
  • Lamotrigine Consumer Information (Wolters Kluwer)
  • Lamotrigine Chewable Dispersible Tablets Consumer Information (Wolters Kluwer)
  • Lamotrigine Extended-Release Tablets Consumer Information (Wolters Kluwer)
  • Lamotrigine Orally Disintegrating Tablets Consumer Information (Wolters Kluwer)
  • Lamotrigine Consumer Information (Cerner Multum)
  • Lamotrigine Advanced Consumer Information (Micromedex)
  • Lamotrigine AHFS DI Monographs (ASHP)

Neurotop retard




Neurotop retard may be available in the countries listed below.


Ingredient matches for Neurotop retard



Carbamazepine

Carbamazepine is reported as an ingredient of Neurotop retard in the following countries:


  • Austria

  • Czech Republic

International Drug Name Search


Napmel




Napmel may be available in the countries listed below.


Ingredient matches for Napmel



Naproxen

Naproxen is reported as an ingredient of Napmel in the following countries:


  • Hungary

International Drug Name Search


Verrutopic AS




Verrutopic AS may be available in the countries listed below.


Ingredient matches for Verrutopic AS



Salicylic Acid

Salicylic Acid is reported as an ingredient of Verrutopic AS in the following countries:


  • Argentina

International Drug Name Search


Salmofar




Salmofar may be available in the countries listed below.


Ingredient matches for Salmofar



Calcitonin

Calcitonin is reported as an ingredient of Salmofar in the following countries:


  • Italy

International Drug Name Search


Doc Cefuroxime




Doc Cefuroxime may be available in the countries listed below.


Ingredient matches for Doc Cefuroxime



Cefuroxime

Cefuroxime is reported as an ingredient of Doc Cefuroxime in the following countries:


  • Luxembourg

International Drug Name Search


Monday, October 24, 2016

Fibricor


Fibricor is a brand name of fenofibric acid, approved by the FDA in the following formulation(s):


FIBRICOR (fenofibric acid - tablet; oral)



  • Manufacturer: AR HOLDING CO INC

    Approval date: August 14, 2009

    Strength(s): 105MG [RLD], 35MG

Has a generic version of Fibricor been approved?


No. There is currently no therapeutically equivalent version of Fibricor available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Fibricor. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Methods of use of fenofibric acid
    Patent 7,569,612
    Issued: August 4, 2009
    Inventor(s): Arnold; Kristin Anne & Feng; Hengsheng
    Assignee(s): Mutual Pharmaceutical Company, Inc.
    Fenofibric acid formulations comprising 105 mg of fenofibric acid are described as well as methods of use thereof. Dosage forms include, for example, immediate-release dosage forms.
    Patent expiration dates:

    • August 20, 2027
      ✓ 
      Patent use: ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH HYPERLIPIDEMIAS




  • Methods of use of fenofibric acid
    Patent 7,741,373
    Issued: June 22, 2010
    Inventor(s): Arnold; Kristin Anne & Feng; Hengsheng
    Assignee(s): Mutual Pharmacuetical Company, Inc.
    Fenofibric acid formulations comprising 105 mg of fenofibric acid are described as well as methods of use thereof. Dosage forms include, for example, immediate-release dosage forms.
    Patent expiration dates:

    • August 20, 2027
      ✓ 
      Patent use: ADJUNCTIVE THERAPY TO DIET TO PATIENTS WITH HYPERTRIGLYCERIDEMIA




  • Methods of use of fenofibric acid
    Patent 7,741,374
    Issued: June 22, 2010
    Inventor(s): Arnold; Kristin Anne & Feng; Hengsheng
    Assignee(s): Mutual Pharmaceutical Company, Inc.
    Fenofibric acid formulations comprising 105 mg of fenofibric acid are described as well as methods of use thereof. Dosage forms include, for example, immediate-release dosage forms.
    Patent expiration dates:

    • August 20, 2027
      ✓ 
      Patent use: ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH ELEVATED CHOLESTEROL AND/OR LIPID LEVELS


    • August 20, 2027
      ✓ 
      Patent use: ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH MIXED DYSLIPIDEMIA




  • Methods of use of fenofibric acid
    Patent 7,915,247
    Issued: March 29, 2011
    Inventor(s): Arnold; Kristin Anne & Feng; Hengsheng
    Assignee(s): Mutual Pharmaceutical Company, Inc.
    Fenofibric acid formulations comprising 105 mg of fenofibric acid are described as well as methods of use thereof. Dosage forms include, for example, immediate-release dosage forms.
    Patent expiration dates:

    • August 20, 2027
      ✓ 
      Patent use: ADJUNCTIVE THERAPY TO DIET TO PATIENTS WITH HYPERTRIGLYCERIDEMIA


    • August 20, 2027
      ✓ 
      Patent use: ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH MIXED DYSLIPIDEMIA


    • August 20, 2027
      ✓ 
      Patent use: ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH HYPERLIPIDEMIAS



See also...

  • Fibricor Consumer Information (Wolters Kluwer)
  • Fibricor Consumer Information (Cerner Multum)
  • Fibricor Advanced Consumer Information (Micromedex)
  • Fenofibric Acid Consumer Information (Wolters Kluwer)
  • Fenofibric Acid Delayed-Release Capsules Consumer Information (Wolters Kluwer)
  • Fenofibric acid Consumer Information (Cerner Multum)
  • Fenofibric acid Advanced Consumer Information (Micromedex)

Vitamine E




Vitamine E may be available in the countries listed below.


In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Vitamine E



Tocopherol, α-

Tocopherol, α- acetate (a derivative of Tocopherol, α-) is reported as an ingredient of Vitamine E in the following countries:


  • France

  • Netherlands

International Drug Name Search


Norvir


Norvir is a brand name of ritonavir, approved by the FDA in the following formulation(s):


NORVIR (ritonavir - capsule; oral)



  • Manufacturer: ABBOTT

    Approval date: June 29, 1999

    Strength(s): 100MG [RLD]

NORVIR (ritonavir - solution; oral)



  • Manufacturer: ABBOTT

    Approval date: March 1, 1996

    Strength(s): 80MG/ML [RLD]

NORVIR (ritonavir - tablet; oral)



  • Manufacturer: ABBOTT LABS

    Approval date: February 10, 2010

    Strength(s): 100MG [RLD]

Has a generic version of Norvir been approved?


No. There is currently no therapeutically equivalent version of Norvir available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Norvir. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Pharmaceutical composition for inhibiting HIV protease
    Patent 5,484,801
    Issued: January 16, 1996
    Inventor(s): Al-Razzak; Laman A. & Marsh; Kennan C. & Manning; Lourdes P. & Kaul; Dilip
    Assignee(s): Abbott Laboratories
    A pharmaceutical composition is disclosed which comprises a solution of an HIV protease inhibiting compound in a pharmaceutically acceptable organic solvent comprising a mixture of (1) (a) a solvent selected from propylene glycol and polyethylene glycol or (b) a solvent selected from polyoxyethyleneglycerol triricinoleate, polyethylene glycol 40 hydrogenated castor oil, fractionated coconut oil, polyoxyethylene (20) sorbitan monooleate and 2-(2-ethoxyethoxy)ethanol or (c) a mixture thereof and (2) ethanol or propylene glycol.
    Patent expiration dates:

    • January 28, 2014


    • July 28, 2014
      ✓ 
      Pediatric exclusivity




  • Retroviral protease inhibiting compounds
    Patent 5,541,206
    Issued: July 30, 1996
    Inventor(s): Kempf; Dale J. & Norbeck; Daniel W. & Sham; Hing Leung & Zhao; Chen
    Assignee(s): Abbott Laboratories
    A retroviral protease inhibiting compound of the formula: ##STR1## is disclosed.
    Patent expiration dates:

    • July 30, 2013
      ✓ 
      Patent use: USE OF NORVIR TO INHIBIT HIV PROTEASE OR TO INHIBIT AN HIV INFECTION


    • July 30, 2013
      ✓ 
      Patent use: METHOD OF USE FOR INHIBITING HIV INFECTION


    • July 30, 2013
      ✓ 
      Patent use: TREATMENT OF HIV-INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS
      ✓ 
      Drug substance
      ✓ 
      Drug product


    • January 30, 2014
      ✓ 
      Pediatric exclusivity




  • Retroviral protease inhibiting compounds
    Patent 5,635,523
    Issued: June 3, 1997
    Inventor(s): Kempf; Dale J. & Norbeck; Daniel W. & Sham; Hing Leung & Zhao; Chen
    Assignee(s): Abbott Laboratories
    A retroviral protease inhibiting compound of the formula: ##STR1## is disclosed.
    Patent expiration dates:

    • July 30, 2013
      ✓ 
      Patent use: USE OF RITONAVIR IN COMBINATION WITH ANY REVERSE TRANSCRIPTASE INHIBITOR


    • June 3, 2014
      ✓ 
      Patent use: USE OF RITONAVIR IN COMBINATION WITH ANY REVERSE TRANSCRIPTASE INHIBITOR


    • July 30, 2013
      ✓ 
      Patent use: METHOD OF USE IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS


    • July 30, 2013
      ✓ 
      Patent use: TREATMENT OF HIV-INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS


    • January 30, 2014
      ✓ 
      Pediatric exclusivity


    • December 3, 2014
      ✓ 
      Pediatric exclusivity




  • Retroviral protease inhibiting compounds
    Patent 5,648,497
    Issued: July 15, 1997
    Inventor(s): Kempf; Dale J. & Norbeck; Daniel W. & Codacovi; Lynn M. & Sham; Hing L. & Wittenberger; Steven J.
    Assignee(s): Abbott Laboraotries
    A retroviral protease inhibiting compound of the formula A--X--B is disclosed. Also disclosed are a composition and method for inhibiting a retroviral protease and for treating an HIV infection. Also disclosed are processes and intermediates useful for the preparation of the retroviral protease inhibitors.
    Patent expiration dates:

    • July 15, 2014


    • July 15, 2014
      ✓ 
      Drug substance


    • January 15, 2015
      ✓ 
      Pediatric exclusivity




  • Retroviral protease inhibiting compounds
    Patent 5,674,882
    Issued: October 7, 1997
    Inventor(s): Kempf; Dale J. & Norbeck; Daniel W. & Sham; Hing Leung & Zhao; Chen
    Assignee(s): Abbott Laboratories
    A retroviral protease inhibiting compound of the formula: ##STR1## is disclosed.
    Patent expiration dates:

    • July 30, 2013
      ✓ 
      Patent use: TREATMENT OF HIV-INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS


    • July 30, 2013
      ✓ 
      Patent use: TREATMENT OF HIV INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS


    • January 30, 2014
      ✓ 
      Pediatric exclusivity




  • Pharmaceutical composition
    Patent 5,948,436
    Issued: September 7, 1999
    Inventor(s): Al-Razzak; Laman A. & Marsh; Kennan C. & Kaul; Dilip & Manning; Lourdes P.
    Assignee(s): Abbott Laboratories
    A pharmaceutical composition is disclosed which comprises a solution of an HIV protease inhibiting compound in a pharmaceutically acceptable organic solvent comprising a pharmaceutically acceptable alcohol. The composition can optionally comprise a pharmaceutically acceptable acid or a combination of pharmaceutically acceptable acids. The solution can optionally be encapsulated in hard gelatin capsules or soft elastic gelatin capsules. The solution can optionally be granulated with a pharmaceutically acceptable granulating agent.
    Patent expiration dates:

    • September 13, 2013
      ✓ 
      Drug product


    • September 13, 2013


    • March 13, 2014
      ✓ 
      Pediatric exclusivity




  • Method for improving pharmacokinetics
    Patent 6,037,157
    Issued: March 14, 2000
    Inventor(s): Norbeck; Daniel W. & Kempf; Dale J. & Leonard; John M. & Bertz; Richard J.
    Assignee(s): Abbott Laboratories
    A method is disclosed for improving the pharmacokinetics of a drug which is metabolized by cytochrome P450 monooxygenase.
    Patent expiration dates:

    • June 26, 2016


    • June 26, 2016
      ✓ 
      Patent use: TREATMENT OF HIV INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS


    • June 26, 2016
      ✓ 
      Patent use: TREATMENT OF HIV-INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS


    • December 26, 2016
      ✓ 
      Pediatric exclusivity




  • Pharmaceutical composition
    Patent 6,232,333
    Issued: May 15, 2001
    Inventor(s): Lipari; John & Al-Razzak; Laman A. & Ghosh; Soumojeet & Gao; Rong & Kaul; Dilip
    Assignee(s): Abbott Laboratories
    A liquid pharmaceutical composition providing improved oral bioavailability is disclosed for compounds which are inhibitors of HIV protease. In particular, the composition comprises a solution in a pharmaceutically acceptable organic solvent of (a) the HIV protease inhibitor and, optionally, (b) a surfactant. The composition can optionally be encapsulated in either hard gelatin capsules or soft elastic capsules (SEC).
    Patent expiration dates:

    • November 7, 2017


    • May 7, 2018
      ✓ 
      Pediatric exclusivity




  • Method for improving pharmacokinetics
    Patent 6,703,403
    Issued: March 9, 2004
    Inventor(s): Daniel W.; Norbeck & Dale J.; Kempf & John M.; Leonard & Richard J.; Bertz
    Assignee(s): Abbott Laboratories
    A method is disclosed for improving the pharmacokinetics of a drug which is metabolized by cytochrome P450 monooxygenase.
    Patent expiration dates:

    • June 26, 2016
      ✓ 
      Patent use: TREATMENT OF HIV IN CONCOMITANT THERAPY


    • June 26, 2016
      ✓ 
      Patent use: TREATMENT OF HIV-INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS


    • December 26, 2016
      ✓ 
      Pediatric exclusivity




  • Pharmaceutical formulations
    Patent 7,141,593
    Issued: November 28, 2006
    Inventor(s): Alani; Laman & Ghosh; Soumojeet
    Assignee(s): Abbott Laboratories
    Improved pharmaceutical compositions are provided comprising one or more solubilized HIV protease inhibiting compounds having improved solubility properties in a medium and/or long chain fatty acid, or mixtures thereof, a pharmaceutically acceptable alcohol, and water.
    Patent expiration dates:

    • May 22, 2020
      ✓ 
      Drug product


    • November 22, 2020
      ✓ 
      Pediatric exclusivity




  • Polymorph of a pharmaceutical
    Patent 7,148,359
    Issued: December 12, 2006
    Inventor(s): Chemburkar; Sanjay R. & Patel; Ketan
    Assignee(s): Abbott Laboratories
    A new crystalline polymorph of ritonavir and methods for its use and preparation are disclosed.
    Patent expiration dates:

    • July 19, 2019
      ✓ 
      Drug product


    • January 19, 2020
      ✓ 
      Pediatric exclusivity




  • Solid dispersion pharamaceutical formulations
    Patent 7,364,752
    Issued: April 29, 2008
    Inventor(s): Fort; James J. & Krill; Steven L. & Law; Devalina & Qiu; Yihong & Porter; William R. & Schmitt; Eric A.
    Assignee(s): Abbott Laboratories
    A pharmaceutical composition is disclosed which comprises a solid dispersion of an HIV protease inhibitor in a water soluble carrier, such as PEG, having enhanced bioavailability and improved dissolution properties. The solid dispersion may optionally be encapsulated in hard gelatin capsules, compressed into a tablet, or may be granulated with a pharmaceutically acceptable granulating agent. Also disclosed are methods of making said solid dispersion and methods of treating an HIV infection employing said solid dispersion.
    Patent expiration dates:

    • November 10, 2020
      ✓ 
      Patent use: TREATMENT OF HIV-INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS
      ✓ 
      Drug product


    • May 10, 2021
      ✓ 
      Pediatric exclusivity




  • Pharmaceutical formulations
    Patent 7,432,294
    Issued: October 7, 2008
    Inventor(s): Alani; Laman & Ghosh; Soumojeet
    Assignee(s): Abbott Laboratories
    Improved pharmaceutical compositions are provided comprising one or more solubilized HIV protease inhibiting compounds having improved solubility properties in a medium and/or long chain fatty acid, or mixtures thereof, a pharmaceutically acceptable alcohol, and water.
    Patent expiration dates:

    • May 22, 2020
      ✓ 
      Drug product


    • November 22, 2020
      ✓ 
      Pediatric exclusivity



See also...

  • Norvir Consumer Information (Drugs.com)
  • Norvir Consumer Information (Wolters Kluwer)
  • Norvir Capsules Consumer Information (Wolters Kluwer)
  • Norvir Solution Consumer Information (Wolters Kluwer)
  • Norvir Consumer Information (Cerner Multum)
  • Norvir Advanced Consumer Information (Micromedex)
  • Norvir AHFS DI Monographs (ASHP)
  • Ritonavir Consumer Information (Wolters Kluwer)
  • Ritonavir Capsules Consumer Information (Wolters Kluwer)
  • Ritonavir Solution Consumer Information (Wolters Kluwer)
  • Ritonavir Consumer Information (Cerner Multum)
  • Ritonavir Advanced Consumer Information (Micromedex)
  • Ritonavir AHFS DI Monographs (ASHP)

Sandoz Timolol




Sandoz Timolol may be available in the countries listed below.


Ingredient matches for Sandoz Timolol



Timolol

Timolol maleate (a derivative of Timolol) is reported as an ingredient of Sandoz Timolol in the following countries:


  • Canada

International Drug Name Search


Spironolakton Nycomed




Spironolakton Nycomed may be available in the countries listed below.


Ingredient matches for Spironolakton Nycomed



Spironolactone

Spironolactone is reported as an ingredient of Spironolakton Nycomed in the following countries:


  • Sweden

International Drug Name Search


Stigmicarpin




Stigmicarpin may be available in the countries listed below.


Ingredient matches for Stigmicarpin



Nimodipine

Nimodipine is reported as an ingredient of Stigmicarpin in the following countries:


  • Greece

International Drug Name Search


Omeprazol La Santé




Omeprazol La Santé may be available in the countries listed below.


Ingredient matches for Omeprazol La Santé



Omeprazole

Omeprazole is reported as an ingredient of Omeprazol La Santé in the following countries:


  • Colombia

International Drug Name Search


Delsal




Delsal may be available in the countries listed below.


Ingredient matches for Delsal



Metamizole

Metamizole sodium monohydrate (a derivative of Metamizole) is reported as an ingredient of Delsal in the following countries:


  • Venezuela

International Drug Name Search


Sunday, October 23, 2016

VisionBlue


VisionBlue is a brand name of trypan blue ophthalmic, approved by the FDA in the following formulation(s):


VISIONBLUE (trypan blue - solution; ophthalmic)



  • Manufacturer: DORC

    Approval date: December 16, 2004

    Strength(s): 0.06% [RLD]

Has a generic version of VisionBlue been approved?


No. There is currently no therapeutically equivalent version of VisionBlue available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of VisionBlue. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with VisionBlue.

See also...

  • VisionBlue Advanced Consumer Information (Micromedex)
  • Vision Blue Consumer Information (Drugs.com)
  • Trypan blue Intraocular Advanced Consumer Information (Micromedex)

Z-Bec




In the US, Z-Bec is a member of the drug class vitamin and mineral combinations and is used to treat Vitamin/Mineral Supplementation and Deficiency.

Ingredient matches for Z-Bec



Lisinopril

Lisinopril dihydrate (a derivative of Lisinopril) is reported as an ingredient of Z-Bec in the following countries:


  • Greece

International Drug Name Search


Norfloxacin-Teva




Norfloxacin-Teva may be available in the countries listed below.


Ingredient matches for Norfloxacin-Teva



Norfloxacin

Norfloxacin is reported as an ingredient of Norfloxacin-Teva in the following countries:


  • Switzerland

International Drug Name Search


Seal and Heal




Seal and Heal may be available in the countries listed below.


Ingredient matches for Seal and Heal



Salicylic Acid

Salicylic Acid is reported as an ingredient of Seal and Heal in the following countries:


  • Poland

International Drug Name Search


Nurofen for children




Nurofen for children may be available in the countries listed below.


Ingredient matches for Nurofen for children



Ibuprofen

Ibuprofen is reported as an ingredient of Nurofen for children in the following countries:


  • Georgia

  • Greece

  • Israel

  • New Zealand

  • Russian Federation

International Drug Name Search


Nitten DM Solone




Nitten DM Solone may be available in the countries listed below.


Ingredient matches for Nitten DM Solone



Dexamethasone

Dexamethasone 21-(sodium 3-sulfobenzoate) (a derivative of Dexamethasone) is reported as an ingredient of Nitten DM Solone in the following countries:


  • Japan

International Drug Name Search


Dorolad




Dorolad may be available in the countries listed below.


Ingredient matches for Dorolad



Dorzolamide

Dorzolamide hydrochloride (a derivative of Dorzolamide) is reported as an ingredient of Dorolad in the following countries:


  • Greece

International Drug Name Search


Seretran




Seretran may be available in the countries listed below.


Ingredient matches for Seretran



Paroxetine

Paroxetine is reported as an ingredient of Seretran in the following countries:


  • Ecuador

Paroxetine hydrochloride (a derivative of Paroxetine) is reported as an ingredient of Seretran in the following countries:


  • Chile

International Drug Name Search


Saturday, October 22, 2016

Novo-Ramipril




Novo-Ramipril may be available in the countries listed below.


Ingredient matches for Novo-Ramipril



Ramipril

Ramipril is reported as an ingredient of Novo-Ramipril in the following countries:


  • Canada

International Drug Name Search


Naproxen BasicPharma




Naproxen BasicPharma may be available in the countries listed below.


Ingredient matches for Naproxen BasicPharma



Naproxen

Naproxen is reported as an ingredient of Naproxen BasicPharma in the following countries:


  • Netherlands

International Drug Name Search


Hicoseen N Antitussivum




Hicoseen N Antitussivum may be available in the countries listed below.


Ingredient matches for Hicoseen N Antitussivum



Dextromethorphan

Dextromethorphan hydrobromide (a derivative of Dextromethorphan) is reported as an ingredient of Hicoseen N Antitussivum in the following countries:


  • Switzerland

International Drug Name Search


Danamet




Danamet may be available in the countries listed below.


Ingredient matches for Danamet



Danazol

Danazol is reported as an ingredient of Danamet in the following countries:


  • Bangladesh

International Drug Name Search


Salbutamol Inhalation




Salbutamol Inhalation may be available in the countries listed below.


Ingredient matches for Salbutamol Inhalation



Salbutamol

Salbutamol sulfate (a derivative of Salbutamol) is reported as an ingredient of Salbutamol Inhalation in the following countries:


  • Australia

International Drug Name Search


Friday, October 21, 2016

Nimesyl




Nimesyl may be available in the countries listed below.


Ingredient matches for Nimesyl



Nimesulide

Nimesulide is reported as an ingredient of Nimesyl in the following countries:


  • Chile

International Drug Name Search


Sivinar




Sivinar may be available in the countries listed below.


Ingredient matches for Sivinar



Simvastatin

Simvastatin is reported as an ingredient of Sivinar in the following countries:


  • Greece

International Drug Name Search


Nitrong




In the US, Nitrong is a member of the following drug classes: antianginal agents, vasodilators and is used to treat Angina, Angina Pectoris Prophylaxis, Heart Attack, Heart Failure and High Blood Pressure.

Ingredient matches for Nitrong



Nitroglycerin

Nitroglycerin is reported as an ingredient of Nitrong in the following countries:


  • Georgia

  • Greece

  • Latvia

  • Lithuania

International Drug Name Search


Urilev




Urilev may be available in the countries listed below.


Ingredient matches for Urilev



Levofloxacin

Levofloxacin is reported as an ingredient of Urilev in the following countries:


  • Bangladesh

International Drug Name Search


Sidopin




Sidopin may be available in the countries listed below.


Ingredient matches for Sidopin



Amlodipine

Amlodipine is reported as an ingredient of Sidopin in the following countries:


  • Bangladesh

International Drug Name Search


Uvédose




Uvédose may be available in the countries listed below.


Ingredient matches for Uvédose



Colecalciferol

Colecalciferol is reported as an ingredient of Uvédose in the following countries:


  • France

  • Luxembourg

International Drug Name Search


Neonatal Conjunctivitis Medications


Definition of Neonatal Conjunctivitis: Neonatal conjunctivitis is a red eye in a newborn caused by irritation, a blocked tear duct, or infection.

Drugs associated with Neonatal Conjunctivitis

The following drugs and medications are in some way related to, or used in the treatment of Neonatal Conjunctivitis. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

Learn more about Neonatal Conjunctivitis





Drug List:


Qlaira




Qlaira may be available in the countries listed below.


UK matches:

  • Qlaira (SPC)

Ingredient matches for Qlaira



Dienogest

Dienogest is reported as an ingredient of Qlaira in the following countries:


  • Austria

  • Bulgaria

  • France

  • Germany

  • Slovakia

  • Sweden

  • Switzerland

  • United Kingdom

Estradiol

Estradiol 17ß-valerate (a derivative of Estradiol) is reported as an ingredient of Qlaira in the following countries:


  • Austria

  • Bulgaria

  • France

  • Germany

  • Slovakia

  • Sweden

  • Switzerland

  • United Kingdom

International Drug Name Search

Glossary

SPC Summary of Product Characteristics (UK)

Click for further information on drug naming conventions and International Nonproprietary Names.

Thursday, October 20, 2016

Doxazosine Disphar




Doxazosine Disphar may be available in the countries listed below.


Ingredient matches for Doxazosine Disphar



Doxazosin

Doxazosin mesilate (a derivative of Doxazosin) is reported as an ingredient of Doxazosine Disphar in the following countries:


  • Netherlands

International Drug Name Search


Omeprazol Flexopharm




Omeprazol Flexopharm may be available in the countries listed below.


Ingredient matches for Omeprazol Flexopharm



Omeprazole

Omeprazole is reported as an ingredient of Omeprazol Flexopharm in the following countries:


  • Germany

International Drug Name Search


Dioderm




Dioderm may be available in the countries listed below.


UK matches:

  • Dioderm 0.1% w/w Cream (SPC)

Ingredient matches for Dioderm



Hydrocortisone

Hydrocortisone is reported as an ingredient of Dioderm in the following countries:


  • Ireland

  • United Kingdom

International Drug Name Search

Glossary

SPC Summary of Product Characteristics (UK)

Click for further information on drug naming conventions and International Nonproprietary Names.

Wednesday, October 19, 2016

Doximar




Doximar may be available in the countries listed below.


Ingredient matches for Doximar



Doxycycline

Doxycycline is reported as an ingredient of Doximar in the following countries:


  • Peru

International Drug Name Search


Rejection Prophylaxis Medications


Drugs associated with Rejection Prophylaxis

The following drugs and medications are in some way related to, or used in the treatment of Rejection Prophylaxis. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.





Drug List:


Niferex




In the US, Niferex (iron polysaccharide systemic) is a member of the drug class iron products and is used to treat Iron Deficiency Anemia.

US matches:

  • Niferex

  • Niferex Elixir

  • Niferex-150

Ingredient matches for Niferex



Ferrous Glycine Sulfate

Ferrous Glycine Sulfate is reported as an ingredient of Niferex in the following countries:


  • Denmark

  • Italy

  • Norway

  • Sweden

Polyferose

Polyferose is reported as an ingredient of Niferex in the following countries:


  • China

  • Hong Kong

  • United States

International Drug Name Search


Zotral




Zotral may be available in the countries listed below.


Ingredient matches for Zotral



Sertraline

Sertraline hydrochloride (a derivative of Sertraline) is reported as an ingredient of Zotral in the following countries:


  • Myanmar

  • Poland

International Drug Name Search


Vivafeks




Vivafeks may be available in the countries listed below.


Ingredient matches for Vivafeks



Fexofenadine

Fexofenadine hydrochloride (a derivative of Fexofenadine) is reported as an ingredient of Vivafeks in the following countries:


  • Turkey

International Drug Name Search


Alternative medicines


Alternative medicines includes various healing systems, such as homeopathy, herbal remedies, naturopathy, chiropractic, acupuncture, etc., that are not regarded as part of orthodox treatment by the medical profession.


Some of these treatments are now accepted to be of value in some circumstances.

See also

  • herbal products
  • nutraceutical products
  • probiotics

Drug List:


Oméprazole Bouchara-Recordati




Oméprazole Bouchara-Recordati may be available in the countries listed below.


Ingredient matches for Oméprazole Bouchara-Recordati



Omeprazole

Omeprazole is reported as an ingredient of Oméprazole Bouchara-Recordati in the following countries:


  • France

International Drug Name Search


Tuesday, October 18, 2016

Volon A solubile




Volon A solubile may be available in the countries listed below.


Ingredient matches for Volon A solubile



Triamcinolone

Triamcinolone 16α,17α-acetonide 21-phosphate dipotassium salt (a derivative of Triamcinolone) is reported as an ingredient of Volon A solubile in the following countries:


  • Germany

International Drug Name Search


Dexifen




Dexifen may be available in the countries listed below.


Ingredient matches for Dexifen



Dexibuprofen

Dexibuprofen is reported as an ingredient of Dexifen in the following countries:


  • Bangladesh

International Drug Name Search


Par Pharmaceutical


Address


Par Pharmaceutical,
300 Tice Boulevard

Woodcliff Lake, NJ 07677

Contact Details

Phone: (201) 802-4000
Website: http://www.parpharm.com/
Careers: http://www.parpharm.com/index.php?option=com_content&view=article&id=78&Itemid=18

Hydase


Hydase is a brand name of hyaluronidase, approved by the FDA in the following formulation(s):


HYDASE (hyaluronidase - injectable; injection)



  • Manufacturer: AKORN INC

    Approval date: October 25, 2005

    Strength(s): 150 UNITS/ML [RLD]

Has a generic version of Hydase been approved?


No. There is currently no therapeutically equivalent version of Hydase available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Hydase. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Hydase.

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • October 25, 2010 - NEW CHEMICAL ENTITY

See also...

  • Hydase injectable Consumer Information (Cerner Multum)
  • Hydase Advanced Consumer Information (Micromedex)
  • Hyaluronidase Consumer Information (Wolters Kluwer)
  • Hyaluronidase injectable Consumer Information (Cerner Multum)
  • Hyaluronidase Subcutaneous, Injection Advanced Consumer Information (Micromedex)

Verapamil Eg




Verapamil Eg may be available in the countries listed below.


Ingredient matches for Verapamil Eg



Verapamil

Verapamil hydrochloride (a derivative of Verapamil) is reported as an ingredient of Verapamil Eg in the following countries:


  • Italy

International Drug Name Search


Dexpanthenol-Hemopharm




Dexpanthenol-Hemopharm may be available in the countries listed below.


Ingredient matches for Dexpanthenol-Hemopharm



Dexpanthenol

Dexpanthenol is reported as an ingredient of Dexpanthenol-Hemopharm in the following countries:


  • Russian Federation

International Drug Name Search


Doxycyclin Chevita




Doxycyclin Chevita may be available in the countries listed below.


In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Doxycyclin Chevita



Doxycycline

Doxycycline hyclate (a derivative of Doxycycline) is reported as an ingredient of Doxycyclin Chevita in the following countries:


  • Austria

International Drug Name Search


Venlafaxin Hexal




Venlafaxin Hexal may be available in the countries listed below.


Ingredient matches for Venlafaxin Hexal



Venlafaxine

Venlafaxine is reported as an ingredient of Venlafaxin Hexal in the following countries:


  • Germany

  • Luxembourg

Venlafaxine hydrochloride (a derivative of Venlafaxine) is reported as an ingredient of Venlafaxin Hexal in the following countries:


  • Austria

International Drug Name Search


Youliver




Youliver may be available in the countries listed below.


Ingredient matches for Youliver



Protoporphyrin Disodium

Protoporphyrin Disodium is reported as an ingredient of Youliver in the following countries:


  • Japan

International Drug Name Search


Venomez




Venomez may be available in the countries listed below.


Ingredient matches for Venomez



Omeprazole

Omeprazole is reported as an ingredient of Venomez in the following countries:


  • India

International Drug Name Search


Scanarin




Scanarin may be available in the countries listed below.


Ingredient matches for Scanarin



Ranitidine

Ranitidine hydrochloride (a derivative of Ranitidine) is reported as an ingredient of Scanarin in the following countries:


  • Indonesia

International Drug Name Search


Novocephal




Novocephal may be available in the countries listed below.


Ingredient matches for Novocephal



Piracetam

Piracetam is reported as an ingredient of Novocephal in the following countries:


  • Austria

International Drug Name Search